Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project by Graham, I. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24666
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Plasma Homocysteine as a Risk Factor 
for Vascular Disease
The European Concerted Action Project
Ian M. Graham, FRCPI; Leslie E. Daly, PhD; Helga M. Refsum, MD; Killian Robinson, MD; Lars E. Brattström, MD, PhD; 
Per M. Ueland, MD; Roberto J. Palma-Reis, MD, PhD; Godfried H. J. Boers, MD; Richard G. Sheahan, MRCPl;
Bo Israelsson, MD, PhD; Cuno S. Uiterwaal, MD, PhD; Raymond Meleady, MRCP!; Dorothy McMaster, PhD;
Petra Verhoef, PhD; Jacqueline Witteman, PhD; Paolo Rubba, MD; Hélène Bellet, MD; Jan C. Wautrecht, MD;
Harold W. de Valk, MD; Armando C. Sales Luis, MD, PhD; Françoise M. Parrot-Roulaud, MD; Kok Soon Tan, MRCP; 
Isabella Higgins; Danielle Garçon, PhD; Maria José Medrano, MD, PhD; Mirande Candito, PhD;
Alun E. Evans, MD; Generoso Andria, MD
Context.— Elevated plasma homocysteine is a known risk factor for atheroscle­
rotic vascular disease, but the strength of the relationship and the interaction of 
plasma homocysteine with other risk factors are unclear.
Objective.— To establish the magnitude of the vascular disease risk associated 
with an increased plasma homocysteine level and to examine interaction effects 
between elevated plasma homocysteine level and conventional risk factors.
Design.— Case-control study.
Setting.— Nineteen centers in 9 European countries.
Patients.— A total of 750 cases of atherosclerotic vascular disease (cardiac, ce­
rebral, and peripheral) and 800 controls of both sexes younger than 60 years.
Measurements.— Plasma total homocysteine was measured while subjects 
were fasting and after a standardized methionine-loading test, which involves the 
administration of 100 mg of methionine per kilogram and stresses the metabolic 
pathway responsible for the irreversible degradation of homocysteine. Plasma co- 
balamin, pyridoxal 5'-phosphate, red blood cell folate, serum cholesterol, smoking, 
and blood pressure were also measured.
Results.— The relative risk for vascular disease in the top fifth compared with the 
bottom four fifths of the control fasting total homocysteine distribution was 2.2 (95% 
confidence interval, 1.6-2.9). Methionine loading identified an additional 27% of at- 
risk cases. A dose-response effect was noted between total homocysteine level and 
risk. The risk was similar to and independent of that of other risk factors, but Inter­
action effects were noted between homocysteine and these risk factors; for both 
sexes combined, an increased fasting homocysteine level showed a more than 
multiplicative effect on risk in smokers and in hypertensive subjects. Red blood cell 
foiate, cobalamin, and pyridoxal phosphate, all of which modulate homocysteine 
metabolism, were inversely related to total homocysteine levels. Compared with 
nonusers of vitamin supplements, the small number of subjects taking such vita­
mins appeared to have a substantially lower risk of vascular disease, a proportion 
of which was attributable to lower plasma homocysteine levels.
Conclusions.— An increased plasma total homocysteine level confers an Inde­
pendent risk of vascular disease similar to that of smoking or hyperlipidemia. it 
powerfully increases the risk associated with smoking and hypertension. It is time 
to undertake randomized controlled trials of the effect of vitamins that reduce 
plasma homocysteine levels on vascular disease risk.
JAMA. 1997;277:1775-1781
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CASE-CONTROL and prospective 
studies indicate that an elevated plasma 
homocysteine level is a powerful risk 
factor for atherosclerotic vascular dis­
ease.1,2 The relationship has been re­
ported for elevated plasma homocyste­
ine levels measured with the subject 
fasting and after a methionine-loading 
test.2 Despite the consistency of these 
reports, methodological problems make 
it difficult to be certain of the strength 
of the relationship and in particular of 
the independence of or interactions be­
tween elevated plasma homocysteine 
level and conventional risk factors.8 Elu­
cidation of these issues is an essential 
part of testing the hypothesis that the 
relationship between elevated plasma 
homocysteine level and vascular disease 
is causal.4,5 The presence of interaction 
effects might modify current approaches 
to vascular disease prevention. In ad­
dition, few studies to date have exam­
ined the risk associated with elevated 
plasma homocysteine levels in women.6*8
Plasma homocysteine levels are de­
termined by both genetic9'11 and nutri­
tional2 factors. Of the latter, supplemen­
tation with folic acid in particular can 
reduce homocysteine levels.12'14 This ob­
servation may have substantial public 
health implications.
With the use of the European Com­
munity Concerted Action structure,15 a 
case-control study was designed with 
the following objectives: (1) to examine 
the relationships between plasma total 
homocysteine (tHcy) and vascular dis­
ease risk in male and female European 
subjects; (2) to study possible interac­
tion effects between plasma tHcy level 
and conventional risk factors; and (3) to 
establish whether the blood levels of the 
nutrients that modulate plasma tHcy 
levels (red blood cell folate, cobalamin, 
and pyridoxal phosphate) relate to vas­
cular disease. In this report, we concen­
trate on the first 2 objectives.
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Table 1.— Inclusion and Exclusion Criteria for 
Cases and Controls
Inclusion Criteria
Cases
Age =s60 y at diagnosis (made within previous 12 
mo)
Coronary heart disease 
Clinical evidence of angina or myocardial 
infarction
Plus: 2-fold or more rise in cardiac enzymes with 
evolutionary ST-T changes or pathological Q 
waves alone or angiographic evidence of 
^70%  stenosis of a major coronary artery 
Cerebrovascular disease 
Clinical evidence of stroke or transient ischemic 
attack
Plus carotid stenosis s50%  on Doppler or angi­
ography or unequivocal atherosclerotic plaque 
on angiography or computed tomographic evi­
dence of cerebral infarction without demon­
strable source of embolism 
Peripheral vascular disease 
Clinical evidence of intermittent claudication or 
clearly diminished foot pulses 
Plus: obstruction of 1 major peripheral artery on 
angiography or Doppler ankle-arm index <0.9  
Controls 
Age s=60 y
Free of overt disease, namely, clinical or investia- 
tive evidence of vascular, renal, hepatic, or 
metabolic disease
Exclusion Criteria
Age >60 y
Recent (^3 mo) major systemic illness, including 
myocardial Infarction 
Evidence of nonatherothrombotic vascular disease, 
namely, vasculitis, fibromuscular dysplasia, 
dissection, or migraine 
Diabetes mellitus 
Renal disease 
Hepatic disease 
Thyroid disease 
Cardiomyopathy 
Pregnancy
Anticonvulsant medication 
Overt psychiatric illness 
Chronic alcohol abuse 
Exposure to nitrous oxide {^3 mo)
SUBJECTS AND METHODS 
Patients
Seven hundred fifty vascular disease 
cases and 800 control subjects younger 
than 60 years, of both sexes, were en­
rolled from 19 centers in 9 European coun­
tries. Inclusion and exclusion criteria are 
listed in Table 1. Cases were required to 
have defined clinical and objective inves­
tigational evidence of vascular disease. 
To reduce biases caused by risk factor 
treatment, centers were asked to recruit 
new or recently diagnosed cases wher­
ever possible. Sixty-nine percent were 
recruited within 1 year of diagnosis. Ex­
clusion criteria for both cases and con­
trols included nonatherosclerotic vascu­
lar disease, cardiomyopathy, pregnancy, 
recent (within 3 months) systemic illness, 
diabetes mellitus, renal, thyroid, or psy­
chiatric illness, anticonvulsant therapy, 
and recent (within 3 months) exposure to 
nitrous oxide.
«
Controls
Controls were free of overt disease. 
Community-based controls drawn from 
random population samples, family prac-
tice registers, and occupational registers 
were considered optimal, and centers were 
asked to recruit such subjects from a geo­
graphical background similar to that of 
cases wherever possible. This necessarily 
pragmatic approach yielded slightly less 
than one half of controls from random 
community samples and one third from 
employee health insurance registers, while 
one sixth were hospital employees. Two 
percent of controls were hospital patients. 
Controls from the 3 main sources were 
similar in terms of the major variables 
studied and plasma tHcy levels.
Variables Examined
Demographic, historical, risk factor,
, and diagnostic data were recorded in 
standardized format .Drug and vita­
min usage were noted. Fasting serologi­
cal measurements were made at least 3 
months after acute systemic illness, such 
as myocardial infarction, which may al­
ter homocysteine levels.13,17
An elevated plasma tHcy level may 
be present in the fasting state or may be 
unmasked by means of a methionine- 
loading test. Blood samples for tHcy es­
timation were taken with the subjects 
fasting and 6 hours after administration 
of methionine, 100 mg/kg, by a stan­
dardized method.16,18 Estimations of tHcy 
were performed centrally in Bergen, 
Norway, by means of a method involv­
ing reduction with sodium borohydride, 
derivatization with monobromobimane, 
high-performance liquid chromatogra­
phy separation, and fluorescence detec­
tion.19 Cobalamin and folate levels were 
estimated by radioimmunoassay and 
pyridoxal phosphate levels by enzymatic 
photometry with high-performance liq­
uid chromatography separation at 
Mimelab-AB, Soraker, Sweden.
Smoking status was determined at the 
time of vascular diagnosis (cases) or at 
methionine loading (controls). Blood 
pressure readings were taken in dupli­
cate both before and after the methio­
nine-loading test.
Definitions of Variables 
for Risk Analysis
Plasma tHcy level was analyzed as a 
categorical variable. An elevated tHcy 
level was defined as one in the top fifth 
of the control distribution (fasting, >12 
pimol/L; postload, ^38 jxmol/L). The in­
crease in tHcy level (postload minus the 
fasting value) also had a cutoff point 
defined by the top fifth of the control 
distribution (>27 fxmol/L). Relative risks 
were estimated with those in the bot­
tom four fifths of the distribution used 
as reference.
Because of the large number of treated 
hypertensive patients and the effect of 
treatment on actual levels, we also ana­
lyzed blood pressure as a categorical vari­
able. Hypertension was deemed to be pre­
sent if the mean of the 4 readings was 160 
mm Hg or more (systolic) or 95 mm Hg 
or more (diastolic), or the subject was 
taking antihypertensive medication.
Smoking was analyzed as a continu­
ous variable in terms of the current to­
tal amount of tobacco smoked expressed 
in equivalent number of cigarettes per 
day. Relative risks for smoking were 
based on a comparison between the risk 
for a smoker of exactly 20 cigarettes per 
day compared with a nonsmoker.
Serum cholesterol level was also ana­
lyzed as a continuous variable, and rela­
tive risks were based on a comparison of 
risks in subjects at the top and bottom 
quintiles of the cholesterol distribution 
in controls, 7.1 mmol/L (275 mg/dL) and 
4.9 mmol/L (189 mg/dL), respectively.
Each case was categorized as one of 
coronary heart, cerebrovascular, or pe­
ripheral vascular disease. If a case had 
several diagnoses, the major manifes­
tation was used.
Statistical Methods
Logarithmic transformations and geo­
metric means were used for variables 
showing a marked positive skew. Analy­
sis of variance, least-squares regression, 
and t test and x2 test were used for 
initial data analysis with 2-tailed levels 
of significance.
Risk analyses were performed by 
means of conditional logistic regression 
for all vascular disease and for the 3 
subcategories separately. All of the con­
trols were used for each category, and 
all risk analyses were stratified by age 
group (<40, 40-49, and 2:50 years), sex 
where relevant, and the 19 centers. Odds 
ratios, which are described in this ar­
ticle as relative risks, together with their 
95% confidence intervals (CIs), were de­
rived from the regression coefficient with 
dummy variables used for the dose-re- 
sponse analysis.
Two risk factors interact with each 
other if the joint effect of the 2 factors 
in combination is different from that ex­
pected on the basis of their separate 
effects. Two models may be used to de­
termine interaction—the additive and 
the multiplicative20—but without a great 
deal of knowledge about the processes 
that lead to disease, it is impossible to 
know which model is more appropriate. 
The multiplicative model tends to be the 
more commonly used because it is the 
model underlying logistic regression,21 
but there have been recent suggestions 
that cardiovascular risk factors may not 
act multiplicatively.22
For the calculation of the observed 
relative risk in those exposed to 2 fac­
tors, a multiplicative interaction term
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TablB 2.—Distribution of Major Variables in Cases and Controls*
' y, r.; v •;!/ ;<r n i;'-> '.•v : ; ?>>f y>\ I
Controls
! . . .  -  
All
Cases
CHD CVA
1
PVD PÍ
No. 800 750 383 211 156 • • *
Mean age, y 43.9 47.2 48.8 43.7 47.8 <.001
Sex, No. (%) male 570 (71.3) 544 (72,5) 322 (84.1) 112(53.1) 110(70.5) .57
GMT fasting total homocysteine, jxmol/L 9.73 11.25 11.16 11.11 11.67 <.001
No, (%) in top fifth 160 (20.0) 274 (36.5) 138 (36.0) 73 (34.6) 63 (40.4) <.001
GMT postload total homocysteine, ¿xmol/L 30.32 35.54 34,44 36.59 36.93 <.001
No. (%) in top fifth 160 (20.0) 285(38.0) 135 (35.3) 87 (41.2) 63 (40.4) <.001
GMT total homocysteine increase, ixmol/LJ: 20.3 23.6 22.9 24.8 24.3 <.001
No. (%) in top fifth 160 (20.0) 241 (32.1) 107 (27.9) 77 (36.5) 57 (36.5) <.001
Mean serum cholesterol, mmol/L (mg/dL) 5.98(231) 6.39 (247) 6.44 (249) 6.20 (240) 6.51 (252) <.001
Mean LDL cholesterol, mmol/L (mg/dL) 4.05(157) 4.42 (171) 4.50(174) 4.25 (164) 4.45 (172) <,001
Mean HDL cholesterol, mmol/L (mg/dL) 1.32 (51) 1,14(44) 1.10(43) 1.22 (47) 1.14(44) <.001
Mean HDlvtotal cholesterol 0.23 0.19 0.18 0.21 0.18 <.001
Mean serum triglycerides, mmol/L (mg/dL) 1.34(119) 1.85 (164) 1.9 (168) 1.62(143) 2.0 (177) <.001
Mean systolic blood pressure, mm Hg 127.0 130.7 127.5 131.4 137.8 <.001
Mean diastolic blood pressure, mm Hg 81.5 82.2 81.4 82.7 83.7 .15
No. (%) with hypertension§ 96 (12.0) 289 (38.5) 152 (39.7) 74 (35.1) 63 (40.4) <.001
No. (%) with any current tobacco use§ 267 (33.4) 408 (54.4) 179 (46.7) 109 (51.7) 120 (76.9) <.001
Mean equivalent cigarettes/d in smokers 16.8 22.4 24.7 19.3 21.7 <.001
GMT red blood cell folate, nmol/L 840.46 811.68 845.67 767.95 778.82 .1
GMT cyanocobalamin, pmol/L 234.62 236.1 232.41 243.47 235.36 ,80
GMT pyridoxal phosphate, nmol/L 31.11 26.32 26.92 27.52 22.73 <.001
No. (%) taking vitamins (pyridoxal/cyanccobalamin/folate) 44 (5.5) 14(1,9) 5 (1.3) 5 (2.4)1) 4(2.6) <.001
Mean serum creatinine, }j.mo(/L (mg/dL) 68.9 (0.78) 70.7 (0.80) 73.4 (0.83) 68.9 (0.78) 68.1 (0.77) .06
*CHD indicates coronary heart disease; CVA, cerebrovascular disease; PVD, peripheral vascular disease; GMT, geometric mean titer; LDL, low-density lipoprotein; and HDL, 
high-density lipoprotein. 
fComparison of all vascular cases and controls. 
iPostload minus fasting total homocysteine.
§See text.
IjOne case missing.
was included in the logistic model even 
if it was statistically nonsignificant, thus 
avoiding the otherwise automatic accep­
tance of a multiplicative model. The ex­
pected joint relative risks, under both 
the multiplicative and additive models, 
were based on the individual relative risks 
for each factor on its own. Significance of 
departure from a particular model was 
based on hypothesis tests on the regres­
sion coefficients.23 The interaction analy­
sis employed a model that included either 
fasting or postload tHcy level, the 3 con­
ventional risk factors (cholesterol, smok­
ing, and blood pressure), and the 3 inter­
actions between the risk factors and the 
particular tHcy level, with age, sex, and 
center as stratification variables.
The need to examine interaction ef­
fects between tHcy and the 3 conven­
tional risk factors necessitated a larger 
sample than that of earlier studies. The 
chosen sample size was based on a par­
ticular quantification of an interaction 
between 2 continuous variables and is 
described elsewhere.16
RESULTS 
Case-Control Differences
Cases were slightly older, had higher 
plasma tHcy, cholesterol, triglyceride, 
and systolic blood pressure levels, and
used more tobacco than controls (Pc.OOl), 
Serum cobalamin levels were similar in 
cases and controls. Red blood cell folate 
levels were nonsignificantly lower and 
serum pyridoxal phosphate levels sig­
nificant!y lower in cases than in controls 
(Table 2). Cases were significantly less 
likely than controls to be taking supple­
ments containing these vitamins. Users 
of supplements containing folic acid, co­
balamin, or pyridoxine had a relative risk 
of 0.38 (95% Cl, 0.2-0.72) compared with 
nonusers (adjusted for conventional risk 
factors).
Geometric mean fasting tHcy levels 
were 16% (95% Cl, 12%-20%) and post­
load tHcy levels 17% (95% Cl, 13%-21%) 
higher in cases than in controls. Similar 
differences were noted in each vascular 
disease category. Arithmetic mean tHcy 
levels were 20% higher in cases for both 
fasting and postload values. The case- 
control differences were explained by a 
shift in the case distribution to the right 
with a more pronounced positive skew 
in cases (Figure 1). In controls, fasting 
tHcy levels were significantly and in­
dependently higher in older subjects and 
in men. Postload levels showed a similar 
association with age but not sex. De­
spite variation in tHcy levels between 
centers, no clear geographical trend was 
apparent, perhaps because of small num­
bers in some southern European cen­
ters. The increase in plasma tHcy level 
(postload minus fasting) was also sig­
nificantly higher in cases than in con­
trols (Table 2),
Relationships between fasting and 
postload total tHcy level were also ex­
amined. Although the measures were 
highly correlated (Figure 2), different 
persons with elevated tHcy levels were 
identified by each measure. A total of 
30.1% (241/800) of controls had elevated 
tHcy levels, either fasting, post load, or 
both, compared with 50% (375/750) of 
cases; 13.5% (101/750) of all cases (26.9% 
[101/375] of cases with elevated tHcy lev­
els) would not have been so classified if 
the postload estimation had not been 
available (Figure 3). An elevated increase 
in plasma tHcy level was defined as an 
increase (postload minus fasting) above 
the top quintile in controls. A farther 18 
controls (2.3%) and 13 cases (1.7%) with 
elevated increases who did not have el­
evated fasting or postload levels were 
identified by this additional measure.
Vascular Disease Risk and Elevated 
Plasma tHcy Levels
In the univariate analysis using pre­
sent definitions, both elevated fasting 
and postload tHcy levels were as 
strongly related to vascular disease and
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Figure 1.— Distribution of fasting and postload plasma total homocysteine levels In vascular disease cases 
(n=750) and controls (n==800).
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Figure 2.— The association between fasting and postload plasma totai homocysteine levels in all vascular 
disease cases and controls. The reference lines are at the control quintile cutoff points used to define el­
evated values. The percentages in circles are the proportion of controls (or cases) with combinations of el­
evated fasting and postload homocysteine levels. For controls the regression equation was log(postload to­
tal homocysteine level)=1.82+ 0 .70  log(fasting total homocysteine level); r -0 ,6 9 ; P< ,001. For cases the 
equation was log(postload total homocysteine level) = 1 .98+0.66  log(fasting total homocysteine level); 
r=0.70; P c .001). Note: log refers to natural log.
its 3 categories as cholesterol level and 
smoking (Table 3). Postload risk was 
greater in women (especially those with 
coronary heart disease) than in men, 
but this was not statistically significant. 
Hypertension was insignificantly more 
strongly related to risk than elevated 
tHcy was. Examination of the increase 
(postload minus fasting level) in tHcy 
level tended to result in somewhat lower 
risk estimates (Table 3).
When adjusted for the presence of the 
conventional risk factors as well as age 
and center, the relative risks for both 
elevated fasting and postload tHcy levels 
were reduced only marginally and re­
mained independent and strong predic­
tors of vascular disease despite the pres­
ence of interaction effects (see below).
The simultaneous effect on vascular 
disease of an elevated fasting, an el­
evated postload, and an elevated increase
in tHcy levels was examined in a single 
logistic regression model (adjusting for 
the 3 classic risk factors). The results 
are presented in Figure 3. Although an 
elevated increase in tHcy level identi­
fied an extra 18 controls and 13 cases 
who did not have elevated fasting or 
postload levels, there was no indepen­
dent effect on risk associated with an 
elevated increase in tHcy. On the other 
hand, an elevated postload level con­
tributed independently to risk. For risk 
analyses, therefore, the effects of an el­
evated increase in tHcy level are not 
considered further. Fasting and post­
load elevations in tHcy had independent 
effects on risk and had a multiplicative 
effect when present together. The rela­
tive risk for a subject with an elevated 
fasting tHcy level only was 1.6 (95% Cl, 
1.0-2.2) and that for an elevated post­
load level only was 1.5 (95% Cl, 1.0-2.2),
Fasting Postload
18/13
0,7
Increase (Postload-Fasting)
A)l Fasting, 1.9 All Postload, 1.8 All Increase, 1.4
Figure 3.— Numbers of subjects (controls/cases) 
with elevated fasting, elevated postload, and el­
evated increase of plasma total homocysteine level 
with associated relative risks (shown in large bold 
type) of vascular disease (adjusted for age, sex, 
center, and other risk factors). Relative risks for all 
subjects with elevated fasting, elevated postload, or 
elevated increase in total homocysteine level are 
shown separately (last line of type).
while for a subject with both elevated 
fasting and postload levels, the relative
risk was 2.5 (95% Cl, 1.7-3.5).
Figure 4 demonstrates the possibility 
of a dose-reponse effect between tHcy 
level and vascular disease risk. Risk be­
gins to rise from the middle of the dis­
tribution, with the increase most appar­
ent beyond the eighth decile (top 
quintile). For this reason, the top fifth of 
the control distribution was compared 
with the bottom four fifths in deriving 
relative risks. Comparing the top 10th 
with the bottom 10th, subjects had a 
relative risk of 3.1 (95% Cl, 1.9-5.2) for 
fasting tHcy and 3.7 (95% Cl, 2.2-6.1) for 
postload tHcy. When tHcy was consid­
ered as a continuous variable, the rela­
tive risk per 5-(xmol/L increment in fast­
ing tHcy level was 1.35 (95% Cl, 1.1-1.6) 
for men and 1.42 (95% Cl, 0.99-2.05) for 
women.
Interactions Between Plasma tHcy 
Level and Other Risk Factors
Figure 5 and Table 4 show the rela­
tive risks in various combinations of tHcy 
levels and the conventional risk factors. 
In men, elevated fasting tHcy level 
showed an additive effect with choles­
terol level and greater than multiplica­
tive interaction with smoking and blood 
pressure. Elevated postload tHcy level 
produced interaction effects that were 
greater than multiplicative with choles­
terol level and greater than additive with 
smoking and blood pressure. Similar in­
teraction effects were apparent in wom-
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Table 3.— Relative Risks (95% Confidence Intervals) for Elevated Fasting, Elevated Postload, and Elevated 
Increase in Plasma Total Homocysteine and Conventional Risk Factors (Adjusted for Age and Center)*
Relative Risk (95% Confidence Interval)
I
All
Vascular CHD CVD
—  ! 
PVD
Men (univariate)
Elevated total homocysteinef
Fasting 2.2 (1.6-2.9) 2.0 (1.4-2.8) 2.1 (1.3-3.5) 2.6 (1.5-4.5)
Postload 1.9 (1.4-2.5) 2.0 (1.4-2.9) 2.1 (1.3*3.6) 1.3 (0.8-2.3)
Increase 1.5 (1.1-2.0) 1.5 (1.0-2.1) 1.7(1.0-2.9) 1.2 (0.7-2.1)
Hypercholesterolemia^ 1.4{1.1-1.7) 1.4 (1.1-1.8) 1.5 (1.0-2.2) 1.5 (1.0-2.3)
Tobacco smoking§ 2.2(1.8-2.7) 1.8 (1.5-2.3) 1.9 (1.3-2.8) 4.4 (2.9-6.7)
Hypertensionll 3.9 (2.8-5.3) 3.6 (2.5-5.2) 4.8 (2.7-S.4) 3.8 (2.1-6.8)
Female (univariate)
Elevated total homocysteinef
Fasting 1.9 {1.1-3.2) 2.3 (1.1-4.8) 1.9 (1.0-3.8) 0.5 (0.2-1.9)
Postload 2.8 (1.7-4.5) 4.2 (1.9-8.7) 1.9(1.0-3.7) 2.1 (0.9-5.1)
Increase 1.9 (1.2-3.1) 2.6 (1.3-5.5) 1,5 (0.8-2.8) 2.3 (1.0-5.5)
Hypercholesterolemia^ 1.6 (1.1-2.3) 1.4 (Û.8-2.3) 1.5 (0.9-2.6) 3.3 (1.5-6.9)
Tobacco smoking§ 4.0 (2.4-6.5) 2.6(1.3-5.3) 3.5 (2.0-6.2) 5.6 (2.5-12.3)
Hypertensionll 8.5 (4.3-17.0) 10.4(4.4-24.4) 6,9 (2.7-17.8) 14.1 (4.1-48,0)
Both sexes (univariate)
Elevated total homocysteinef
Fasting 2.1 (1.6-2.7) 2.1 (1.5-2.8) 2.0 (1.4-3.1) 2.0 (1.2*3,1)
Postload 2.1 (1.6-2.7) 2.3 (1.7-3.2) 2.1 (1,4-3.1) 1.5(1.0-2.4)
Increase 1.6(1.2-2.0} 1,7(1.2-2.3) 1,6 (1.1-2.4) 1.4 (0,9-2.3)
Both sexes (adjusted for 
conventional risk factors) 
Elevated total homocysteinef
Fasting 1.9 (1.4-2.4) 2.0 (1.4-2.8) 1.7(1,1-2.7) 1.7 (1.0-2,9)
Postload 1.8 (1.4-2.4) 2.0 (1.4-2.8) 1.9 (1.2-2.9) 1.2 (0.7-2.1)
Increase 1.4 (1.1-1.9) 1.4 (1.0-2.0) 1.4 (0.9-2.2) 1,1 (0.6-1.9)
*CHD indicates coronary heart disease; CVD, cerebrovascular disease; and PVD, peripheral vascular disease, 
f  For those above the top quintile compared with remainder.
t Continuous variable: re ative risk for individual with a cholesterol level of 7.1 mmol/L (275 mg/dL) compared with 
an individual with a cholesterol level of 4.9. mmol/L (189 mg/dL).
§Continuous variable: relative risk for smoker of 20 cigarettes per day (or equivalent) compared with a nonsmoker. 
¡[Categorical variable: relative risk for individual with a systolic blood pressure of 160 mm Hg or more or diastolic 
blood pressure of 95 mm Hg or more or receiving antihypertensive treatment compared with remainder.
en and in many of the individual vascu­
lar disease categories.
COMMENT
This study addresses the strength and 
possible independence of the relation­
ship between plasma tHcy level and all 
categories of atherosclerotic vascular 
disease. The design and power of the 
study were sufficient to allow examina­
tion of interaction effects between tHcy 
level and conventional risk factors. These 
relationships may have considerable im­
plications for public health.
In the present study, subjects with 
plasma tHcy levels in the top fifth of the 
control distribution, either fasting or 
after methionine loading, had a 2-fold 
increase in vascular disease risk com­
pared with the remaining four fifths. 
This level of risk was equivalent to that 
of hypercholesterolemia or smoking and 
applied to all categories of vascular 
disease. It is lower than earlier esti­
mates of risk because of the lower cutoff 
point chosen to define elevated tHcy 
level and for this reason applies to a 
much larger proportion of the popula­
tion. The risk estimate was also inde-
pendent of the effect of other risk 
factors.
Fasting and postload tHcy levels were 
highly interrelated. The former may re­
flect cobalamin- and folate-dependent 
remethylation, and the latter, pyridoxal 
5'-phosphate-dependent transsulfura­
tion.24,25 Reliance on fasting tHcy level 
alone will result in classifying 27% fewer 
patients as hyperhomocysteinemic. Bos- 
tom and colleagues26 reported that use 
of fasting tHcy level alone would have 
led to classification of more than 40% 
fewer subjects as being hyperhomocys- 
teinemic.
The risk associated with elevated post­
load tHcy was higher in women, par­
ticularly those with coronary heart dis­
ease. While not statistically significant, 
this finding may be clinically relevant if 
confirmed in larger numbers of subjects. 
It is possible that the age cutoff point of 
60 years selected particularly high-risk 
women. A similar effect might partially 
explain the high risk associated with 
hypertension in women.
The strong, independent association 
between elevated tHcy level and vas­
cular disease risk is consistent with other
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Figure 4.— Relative risks of vascular disease in 
groups defined by deciles (in controls) of fasting and 
postload plasma total homocysteine level with 95%  
confidence intervals (adjusted for age, sex, center, 
cholesterol, smoking, and blood pressure).
case-control1 and most27'32 but not all33 
prospective studies. Boushey et al1 es­
timated that the odds ratio for coronary 
artery disease of a S-jxmol/L increment 
in plasma homocysteine level is 1,6 (95% 
Cl, 1.4-1.7) for men and 1.8 (95% Cl, 
1.3-1.9) for women, equivalent to an in­
crease in cholesterol level of 0.5 mmol/L 
(19 mg/dL), Corresponding risks in the 
present study are 1.3 (95% Cl, 1.1-1.6) 
for men and 1.4 (95% Cl, 1.0-2.0) for 
women.
If the top 10th of the tHcy distribution 
is compared with the bottom 10th, the 
corresponding relative risks were 3,1 for 
elevated fasting and 3.7 for elevated post­
load tHcy levels. Figure 4 suggests a dose- 
response effect, an observation supported 
by case-control34 and prospective29^31 data. 
Severe, genetic hyperhomocysteinemia, 
irrespective of the enzyme defect causing 
it, is almost invariably associated with 
premature and aggressive vascular dis­
ease.0 Biologically plausible mechanisms 
of vascular damage have been suggested,1 
including effects on the endothelium, 
platelet function, coagulation factors, and 
lipoprotein oxidation. Many of these stud­
ies require confirmation, and some used 
nonphysiologically high doses of homo­
cysteine.2 While these observations 
strongly suggest a causal relationship be-
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Figure 5.— Relative risks of vascular disease in groups defined by the presence or absence of classic risk 
factors and elevated plasma total homocysteine levels (adjusted for age, sex, and center; see text).
Table 4.— Observed and Expected Relative Risks of All Vascular Disease in All Subjects With Elevated 
Plasma Total Homocysteine and 1 Other Conventional Risk Factor*
Relative Risk
Expected
* i
Observed
I
Multiplicative
Model
I
Additive
Model
Elevated fasting total homocysteine and . . •
Hypercholesterolemia 2.1 2.6 2.2
Smoking 4.6 4.5 3.3
Hypertension 11.3 8.2 5.4t
Elevated postload total homocysteine and t
Hypercholesterolemia 2.5 2.4 2.1
Smoking 5.1 4.4 3.2*
Hypertension 7.8 9.1 5.9
* Adjusted for sex, age, center, and the single and combined effects of the other risk factors and the relevant total 
homocysteine level.
f  P<.05 comparing observed with expected.
£P<.1 comparing observed with expected.
tween elevated plasma homocy steine lev­
els and vascular disease, randomized con­
trolled trial evidence of benefit arising 
from homocysteine reduction is lacking.
Plasma homocysteine concentration 
relates inversely to blood levels of fo­
late, cobalamin, and pyridoxine and to 
intakes of these vitamins.2,36 The pre­
sent study confirms this observation 
(data not shown). In this study, users of 
vitamin preparations containing these 
nutrients appear to experience substan­
tial protection from vascular disease, 
with a relative risk of 0.38 (95% Cl, 0.2-
0.72) compared with nonusers of vita­
mins. However, this observation applies 
to a small number of subjects who may 
have been more health conscious in other 
ways and cannot be taken as proof of 
benefit of the known homocysteine-low­
ering effect of these nutrients.
Interactions between plasma tHcy 
level and conventional risk factors may 
have implications for risk management 
and for our understanding of the causes 
of vascular disease. The joint effect of 
smoking and elevated plasma tHcy level 
was compatible with a multiplicative in-
ter action effect in both sexes combined. 
An even stronger interaction between 
elevated fasting tHcy level and hyper­
tension was noted, especially in women. 
It is conceivable that tHcy may aug­
ment smoking-related platelet and clot­
ting effects or exert a toxic effect on the 
endothelium, and these might be more 
relevant to the genesis of vascular dis­
ease than reported effects of homocys­
teine and lipoprotein oxidation.86,37 Con­
trol of smoking and hypertension may 
be particularly important in subjects 
with elevated tHcy levels, and estima­
tion of plasma tHcy should now be con­
sidered as part of total vascular disease 
risk assessment.
We conclude that an elevated plasma 
tHcy level is now established as a strong 
and independent factor associated with 
all categories of atherosclerotic disease 
in both men and women. An elevated 
plasma tHcy level interacts strongly with 
smoking and hypertension. It is known 
that folate supplementation reduces ho­
mocysteine levels both in the fasting state 
and after methionine loading,12'14,24 and 
that pyridoxal 5'-phosphate can lower 
postmethionine homocysteine levels. Us­
ers of these vitamins have lower homo­
cysteine levels than nonusers do,38 and 
there is a suggestion of reduced risk in 
vitamin users in the present study. We 
believe it is time to consider whether ex­
isting recommended daily allowances of 
the vitamins that modulate homocyste­
ine metabolism are adequate, and to un­
dertake randomized controlled trials of 
the effects of folic acid and perhaps pyri­
doxine in the secondary prevention of car­
diovascular disease.
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